TipRanks
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35
RatingsSarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35
5d ago
SRPT
Sarepta presents new preclinical data at 22nd Meeting of OTS on SRP-1003
PremiumThe Fly
Sarepta presents new preclinical data at 22nd Meeting of OTS on SRP-1003
7d ago
SRPT
Sarepta price target lowered to $17 from $19 at RBC Capital
PremiumThe Fly
Sarepta price target lowered to $17 from $19 at RBC Capital
13d ago
SRPT
Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target
PremiumRatings
Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target
16d ago
SRPT
Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
PremiumRatings
Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
21d ago
SRPT
Sarepta presents new data on ELEVIDYS in DMD at WMS Congress
PremiumThe FlySarepta presents new data on ELEVIDYS in DMD at WMS Congress
21d ago
SRPT
Sarepta price target lowered to $20 from $23 at JPMorgan
Premium
The Fly
Sarepta price target lowered to $20 from $23 at JPMorgan
21d ago
SRPT
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Premium
Ratings
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
23d ago
SRPT
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
PremiumRatings
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
23d ago
SRPT
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
PremiumCompany Announcements
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
28d ago
8K
SRPT
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
PremiumThe Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
1M ago
GS
MS
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
PremiumRatings
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
1M ago
SRPT
Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’
PremiumThe FlyJefferies says definitive readthrough to Sarepta from Novartis news ‘premature’
1M ago
NVS
SRPT
Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone
Premium
The Fly
Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone
1M ago
NVS
SRPT
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
Premium
Ratings
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
1M ago
SRPT
H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss
PremiumThe Fly
H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss
1M ago
NVS
SRPT
Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
PremiumCompany Announcements
Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
2M ago
SRPT
Unusually active option classes on open August 7th
PremiumThe Fly
Unusually active option classes on open August 7th
3M ago
CCJ
PCG
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
PremiumCompany Announcements
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
3M ago
SRPT
Sarepta price target lowered to $35 from $37 at Oppenheimer
PremiumThe FlySarepta price target lowered to $35 from $37 at Oppenheimer
3M ago
SRPT
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
Premium
Ratings
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
3M ago
SRPT
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
Premium
Ratings
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
3M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >